Investor Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Shareholder Letter - August 2018

Press Releases

Date Title and Summary
Toggle Summary Rexahn Pharmaceuticals Granted European Patent for Anti-cancer Compound RX-3117
Rexahn Pharmaceuticals Granted European Patent for Anti-cancer Compound RX-3117 Rexahn Pharmaceuticals Granted European Patent for Anti-cancer Compound RX-3117 Rockville, MD, January 19, 2010 – Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing
Toggle Summary Rexahn Announces $5.3 Million At Market Registered Direct Offering
Rexahn Announces $5.3 Million At Market Registered Direct Offering Rexahn Announces $5.3 Million At Market Registered Direct Offering Rockville, MD, October 11, 2013 – Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) today announced it has received commitments from certain institutional investors to
Toggle Summary Rexahn Pharmaceuticals Announces Formation of Parkinson’s Disease Scientific Advisory Board
Rexahn Pharmaceuticals Announces Formation of Parkinson’s Disease Scientific Advisory Board Rexahn Pharmaceuticals Announces Formation of Parkinson’s Disease Scientific Advisory Board Rockville, MD, March 22, 2010 – Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical

Events & Presentations

Date Event Details
Summary Toggle Sep 6, 2018
9:35 AM EDT
Sep 6, 2018 9:35 AM EDT 09/06/18
Summary Toggle Jun 1-5, 2018 Jun 1, 2018 06/01/18

Title:   Preliminary Results From an Ongoing Phase 2a Study of RX, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer (aUC)  [View Poster]

Title:  Preliminary Report of A Phase 1b/2a Trial, An Oral Inhibitor of Phosphorylated P68 (P-p68),  Which Mediates β-catenin Nuclear Translocation in Advanced Triple-Negative Breast Cancer (TNBC)    [View Poster]

Summary Toggle Apr 14-18, 2018 Apr 14, 2018 04/14/18

Title: RX-3117 promotes epigenetic effects in cancer cells through enhanced degradation of DNMT1 [View Poster]

Location

Chicago, Illinois


©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy